Unity Biotechnology (UBX) AI Stock Analysis

• Market Cap: $19.23M
• Dividend Yield: N/A
• Average Volume (3M): 178.75K
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: N/A
• EPS Growth: 47.26%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -1.54
• Shares Outstanding: 16,867,647
• 10 Day Avg. Volume: 292,001
• 30 Day Avg. Volume: 178,750
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 6.34
• Price to Cash Flow (P/CF): -1.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: 284.62% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Unity Biotechnology's stock score reflects significant financial challenges, with continuous losses and negative cash flows being primary concerns. The company's stock is trading in a bearish technical pattern, indicating potential further declines. However, the appointment of a seasoned expert to the board offers a strategic advantage that could improve the company's future prospects in biotechnology.

Positive Factors

Drug Performance

UBX1325 explicitly achieved non-inferiority to aflibercept for 9 out of 10 time points through 36 weeks, reflecting a completely novel approach in retinal disease.

Earnings

The analyst's recommendation remains 'Outperform' with a price target of $6.00, indicating confidence in the stock's future performance.

Treatment Option

UBX1325 showed outperformance of aflibercept for patients with less aggressive disease, suggesting a prospective option for 2L treatment subsequent to standard of care anti-VEGF.

Negative Factors

Data Imbalance

There were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.

Endpoint Miss

The study missed the primary endpoint of non-inferiority vs aflibercept using the average of 20-week and 24-week BCVA letters change from baseline.

Trial Results

The Phase 2B ASPIRE study of intravitreal foselutoclax (UBX1325) in diabetic macular edema patients did not meet the non-inferiority analysis specifically at the average of weeks 20 and 24 for the primary analysis.

Unity Biotechnology Business Overview & Revenue Model

Company Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

How the Company Makes Money

Unity Biotechnology makes money through the development and commercialization of its therapeutic products targeting senescent cells. The company's revenue model primarily relies on milestone payments, licensing deals, and potential royalties from partnerships with larger pharmaceutical companies. Unity may also generate income from collaborations with other biotech firms or research institutions, which can provide funding for research and development activities. Additionally, the company might raise capital through public or private investments to support its ongoing research and clinical trials, which are crucial for bringing its products to market.

Unity Biotechnology Financial Statement Overview

Summary

Unity Biotechnology faces significant financial challenges with zero revenue and continuous losses affecting its financial health. High leverage and negative cash flows pose risks, while liquidity from cash reserves offers limited short-term relief. The company's focus on R&D may delay profitability, requiring strategic changes to improve financial performance.

Income Statement

The company has consistently reported zero revenue in recent years, with a significant net loss of $25.99 million in 2024. EBIT and EBITDA margins are negative due to high operating costs and no revenue generation, indicating financial instability and a challenging path to profitability.

Balance Sheet

Unity Biotechnology's balance sheet shows a high debt-to-equity ratio due to decreasing equity and increasing debt levels. The equity ratio is low, reflecting financial risk. However, cash reserves of $23.23 million provide some liquidity, although the declining trend in stockholders' equity is concerning.

Cash Flow

The company reported a negative free cash flow and operating cash flow in recent years, indicating cash burn without revenue generation. The lack of operating cash inflow highlights reliance on financing activities, which may not be sustainable long-term.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	236.00K	4.78M	0.00
	Gross Profit
0.00	-19.70M	-1.94M	1.90M	-3.45M
	EBIT
-31.17M	-44.67M	-57.57M	-56.66M	-93.93M
	EBITDA
-31.17M	-37.28M	-38.73M	-54.67M	-89.10M
	Net Income Common Stockholders
-25.99M	-39.86M	-57.75M	-60.04M	-91.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.23M	43.20M	94.80M	88.08M	97.70M
	Total Assets
37.66M	65.69M	124.35M	124.71M	156.32M
	Total Debt
19.71M	26.99M	47.36M	51.56M	58.98M
	Net Debt
12.13M	7.19M	34.62M	18.65M	41.17M
	Total Liabilities
31.17M	37.29M	57.50M	65.14M	73.44M
	Stockholders Equity
6.49M	28.40M	66.85M	59.57M	82.88M
Cash Flow		Free Cash Flow
-20.86M	-37.10M	-51.13M	-45.26M	-78.98M
	Operating Cash Flow
-20.86M	-38.65M	-51.03M	-45.06M	-78.33M
	Investing Cash Flow
8.56M	60.49M	-24.55M	39.31M	-5.21M
	Financing Cash Flow
77.00K	-16.34M	54.85M	20.84M	63.88M

Unity Biotechnology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UBX, the sentiment is Negative. The current price of 1.04 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.85, and below the 200-day MA of 1.49, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 27.67 is Positive, neither overbought nor oversold. The STOCH value of 6.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UBX.

Unity Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRPT	68 Neutral	$6.83B	29.54	19.71%	―	52.97%	―
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
CRIS	48 Neutral	$19.64M	―	-634.71%	―	0.44%	16.44%
FATE	42 Neutral	$97.33M	―	-54.21%	―	-78.55%	-0.92%
BTAI	39 Underperform	$6.98M	―	82.91%	―	64.20%	73.71%
UBX	34 Underperform	$19.23M	―	-148.97%	―	―	47.26%

Unity Biotechnology Corporate Events

Unity Biotechnology Appoints Dr. Yehia Hashad to Board

On March 8, 2025, UNITY Biotechnology appointed Dr. Yehia Hashad to its Board of Directors and Science Committee. Dr. Hashad, an experienced ophthalmologist and executive at Bausch + Lomb, brings over 25 years of leadership in global research and development. His expertise is expected to aid UNITY in advancing its UBX1325 program for diabetic macular edema and other ophthalmologic treatments, potentially enhancing the company’s strategic positioning in the biotechnology sector.